Table 3

Base case cost-effectiveness results for usage of UKR subgroups

TKRUKR∆ QALYs∆ Costs (£)ICER (probability UKR cost-effective*)
QALYsCosts (£)QALYsCosts (£)
UKR <10%8.67
(8.53 to 8.80)
13 267
(12 834 to 13 731)
8.62
(8.38 to 8.84)
13 140
(12 643 to 13 614)
−0.04
(−0.32 to 0.21)
−127
(−429 to 127)
£3000/QALY (37%)
UKR ≥10%8.81
(8.73 to 8.88)
13 170
(12 726 to 13 614)
9.06
(8.94 to 9.18)
12 411
(11 978 to 12 856)
0.26
(0.12 to 0.40)
−758
(−939 to −579)
UKR dominant (100%)
  • Expected (mean) values with 95% CIs in parentheses. UKR is considered ‘dominant’ if it is expected to improve health outcomes and reduce healthcare costs.

  • *Given a cost-effectiveness threshold of £20 000.

  • ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years; TKR, total knee replacement; UKR, unicompartmental knee replacement.